BridgeBio Oncology Therapeutics Inc.
Price Action
Technical Summary
WEAKENINGBridgeBio Oncology Therapeutics Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 23), showing significant lag compared to the market leaders. Earnings contraction of 44% provides fundamental context to the price action. Investors should exercise caution due to high volatility (67% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $7.69 | +7.77% | ABOVE |
| 50 SMA | $8.13 | +2.01% | ABOVE |
| 100 SMA | $8.84 | -6.23% | BELOW |
| 150 SMA | $9.91 | -16.38% | BELOW |
| 200 SMA | $10.42 | -20.44% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BBOT in an uptrend right now?
BBOT has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is BBOT overbought or oversold?
BBOT's RSI (14) is 59. The stock is in neutral territory, neither overbought nor oversold.
Is BBOT outperforming the market?
BBOT has a Relative Strength (RS) Rating of 23 out of 99. BBOT is currently lagging the broader market.
Where is BBOT in its 52-week range?
BBOT is trading at $8.29, which is 56% of its 52-week high ($14.87) and 16% above its 52-week low ($7.01).
How volatile is BBOT?
BBOT has a Beta of 1.24 and 52-week volatility of 67%. It's more volatile than the S&P 500 - expect bigger swings.